Marker Therapeutics, Inc. Annual Report - How They Did This Year

Thinking about investing in Marker Therapeutics, Inc.? You've come to the right place. We're breaking down their latest annual report in plain English, just like we're chatting over coffee. No fancy finance jargon, just the essential information you need to understand the company's performance and what it might mean for your money.

1. What does this company do and how did it perform this year?

Marker Therapeutics is a clinical-stage biotechnology company that develops advanced cell therapies, specifically a type called MAR-T cell therapies (formerly multiTAA T cells). These therapies harness the body's immune system to fight cancer by recognizing multiple tumor-associated antigens (TAAs) simultaneously, aiming for a more robust and lasting anti-tumor response. Its lead product candidate, MT-401, is currently in a Phase 1 clinical trial for acute myeloid leukemia (AML) patients who have received a stem cell transplant. The company also explores other indications and develops additional candidates using its proprietary platform.

For the fiscal year ending December 31, 2025, the most critical takeaway is the "going concern" warning from its independent auditors. This serious red flag indicates significant doubt about the company's ability to operate for the next 12 months without substantial additional funding. Essentially, Marker Therapeutics spends more cash than it generates and needs to raise more capital to continue its research and development.

As of December 31, 2025, the company's market capitalization was approximately $17.3 million, with each share trading around $1.53. By March 16, 2026, approximately 16.7 million shares of common stock were outstanding. As a "Smaller reporting company," Marker Therapeutics has fewer disclosure requirements than larger public companies. This means investors might receive less detailed financial and operational information.

2. Financial performance - revenue, profit, growth metrics

As a clinical-stage biotech company, Marker Therapeutics currently generates minimal or no revenue from product sales. For the fiscal year ended December 31, 2025, the company reported a net loss of approximately $30.5 million, a slight increase from $28.0 million in the prior year. This loss primarily stems from significant investments in research and development (R&D) activities, totaling about $20.0 million for the year, and general and administrative (G&A) expenses of approximately $10.0 million. Such ongoing losses are typical for companies at this development stage, as they focus on advancing therapies through costly clinical trials.

3. Major wins and challenges this year

While the company reported no major commercial wins, it continued to advance its clinical programs. Key progress included:

• Continued enrollment in the Phase 1 trial for MT-401 in AML, showing ongoing clinical activity.
• Advanced preclinical research to expand its MAR-T cell platform to other cancer types, indicating future pipeline potential.
• Maintained key collaborations, such as with Baylor College of Medicine, crucial for its research and development.

The most significant challenge, by far, remains the "going concern" warning due to its limited cash reserves and high burn rate. Beyond this immediate financial hurdle, Marker Therapeutics faces the inherent difficulties of a biotech company:

• Demonstrating sufficient efficacy and safety for MT-401 to progress to later stages.
• Securing regulatory approvals, which involves navigating a complex and lengthy process with health authorities like the FDA.
• Raising sufficient capital to continuously secure additional funding to sustain operations and clinical development.
• Manufacturing complexities in scaling up and reliably producing complex cell therapies.
• Intense competition in a crowded and rapidly evolving cell therapy landscape.

4. Financial health - cash, debt, liquidity

Marker Therapeutics' financial health is currently precarious. As of December 31, 2025, the company reported approximately $15.0 million in cash and cash equivalents. With an estimated average monthly cash burn rate of $3.0 - $4.0 million, this cash balance is insufficient to fund operations for the next 12 months, directly triggering the "going concern" warning. While the company carries minimal long-term debt, its liquidity is severely constrained. To address this, Marker Therapeutics explicitly states it needs to secure "additional funding" through equity offerings, debt financing, or strategic partnerships. This means existing shareholders could face dilution if the company issues new shares, or it could incur interest expenses if it takes on debt.

5. Key risks that could hurt the stock price

Investing in Marker Therapeutics carries several significant risks, amplified by its early stage and financial situation:

• Running out of money (Going Concern): This is the paramount risk. If the company fails to raise substantial additional capital, it severely jeopardizes its ability to continue operations and fund clinical trials, potentially leading to bankruptcy.
• Clinical trial failures or delays: The success of MT-401 and other candidates is uncertain. Negative results, unexpected side effects, or delays in patient enrollment or trial completion could significantly devalue the company.
• Regulatory hurdles: Even with positive trial data, obtaining FDA approval is a long, complex, and uncertain process. A rejection or significant delays would be a major setback.
• Intense competition: The cell therapy market is highly competitive, with larger pharmaceutical companies and other well-funded biotechs developing similar or superior treatments.
• Intellectual property protection: Protecting its MAR-T cell platform and specific product candidates through patents is crucial. Challenges to its intellectual property (IP) could erode its competitive advantage.
• Manufacturing and supply chain risks: Producing complex cell therapies is challenging. Issues with quality, scalability, or cost could hinder future commercialization.
• Reliance on key personnel and collaborations: Losing key scientific or management talent, or terminating critical partnerships (like with Baylor College of Medicine), could severely impact its progress.
• Dilution from future financing: To raise necessary capital, the company will likely issue more shares, which could dilute existing shareholders' investments.

6. Competitive positioning

Marker Therapeutics operates in the highly competitive and rapidly evolving field of cancer cell therapies. Its multi-target MAR-T cell approach aims to differentiate it from single-target CAR-T therapies. However, it faces competition from established players like Novartis (Kymriah), Gilead/Kite Pharma (Yescarta, Tecartus), and Bristol Myers Squibb (Breyanzi, Abecma). Numerous other biotech companies are also developing novel cell therapies, gene therapies, and immunotherapies for various cancers, including AML. Its competitive advantage hinges on demonstrating superior efficacy, safety, and durability with its multi-target approach in clinical trials, especially for indications where existing treatments are limited or ineffective.

7. Leadership or strategy changes

The company maintained its executive leadership team and board of directors during the past fiscal year. Its core strategy remains focused on advancing its MAR-T cell platform through clinical development, with MT-401 as the lead candidate, and exploring new indications and partnerships. However, the company's strategy is heavily influenced by its need to secure additional funding, which may necessitate strategic adjustments or program prioritization.

8. Future outlook

Marker Therapeutics' future depends entirely on the successful clinical development of its MAR-T cell therapies and, most critically, its ability to secure substantial additional funding. Key future plans include:

• Continue enrollment and report data from the MT-401 Phase 1 trial. The company anticipates providing further updates on clinical progress and potential next steps for this program in 2026.
• Advance preclinical programs to explore new targets and indications for its MAR-T cell platform to build a robust pipeline.
• Seek strategic partnerships to collaborate with larger pharmaceutical companies for funding, expertise, and commercialization capabilities.
• Secure significant capital. This is the most immediate and critical objective, as all other plans depend on sufficient financial resources.

The company's ability to achieve these goals faces significant uncertainties and risks, particularly given the "going concern" warning. Without successful fundraising, its operational capacity and clinical development efforts will be severely limited.

9. Market trends or regulatory changes affecting them

The broader cell therapy market is experiencing rapid innovation and growth, driven by advancements in gene editing and immunotherapy. This trend presents both opportunities and challenges for Marker Therapeutics. While demand for effective cancer treatments is high, the regulatory landscape for cell therapies is complex and evolving, with stringent safety and manufacturing requirements. Regulatory bodies like the FDA increasingly focus on accelerating promising therapies through designations like Orphan Drug or Fast Track, which Marker Therapeutics may pursue. However, the high cost of developing and potentially commercializing cell therapies, coupled with evolving reimbursement policies, also poses a significant market challenge.